So many innovations, so little time. To save you some searching, here’re this month’s top 8 innovation picks. Let’s keep the conversation going —…

Let’s keep the conversation going — use hashtag #sparkofinnovation to join the conversation on Twitter and Facebook!

Mice and rats are go-to animal models for research.  A recent report out of the European Union demonstrated the dominance of these rodents…

Working on the Rare Disease Science Challenge has shown me that everybody wants to support rare disease in many different ways, which is…

The US presidential election will soon come to a close today and many Americans will have casted their vote for the candidate who…

Our latest infographic touches on a subject we care deeply about: the cost of drug discovery and the need for cost-effective research and…

Animal testing is critical to advancing science and learning more about disease, but what animals are effective? It’s safe to say that mice,…

The 2011-2012 school year is over, so we decided the next infographic should take a look at how the sciences are faring at…

We’ve looked at what happens to a drug when a patent expires, but what happens to the patent owner? As patents have expired and many blockbuster drugs become generic, pharmaceutical companies have looked to new drugs and innovations to replace the lost income. Getting a drug through regulatory hurdles, such as clinical trials and safety testing, is difficult and millions of dollars can be lost from an unexpected failure. As many patents have expired and only a few drugs have replaced them in the past decade, pharmaceutical companies have looked to mergers and acquisitions for new products and drugs in an effort to buy innovation.